Literature DB >> 2888477

Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine.

L Gramstad1.   

Abstract

Dose-response relations for atracurium, vecuronium and pancuronium were determined in patients in end-stage renal failure for the initial neuromuscular blockade (using three cumulative doses) and for the maintenance of stable 90% response (during continuous infusion). All measurements were during renal transplant surgery, and the interaction of azathioprine on neuromuscular blockade was estimated. Mean ED95 doses were (microgram kg-1): atracurium 375.6, vecuronium 67.2, pancuronium 86.6; the initial blockade required significantly larger doses than in normal patients (37%, 20% and 45%, respectively, using ED50 values). Mean infusion rates for 90% sustained blockade in renal failure were (microgram kg-1 h-1): atracurium 409.4, vecuronium 78.3, pancuronium 14.2. The atracurium dose was not influenced by renal function, whereas vecuronium and pancuronium requirements were significantly reduced by 23.2% and 61.5%, respectively, compared with normal patients (previous study). Azathioprine was injected at the rate of 1 mg kg-1 min-1 for 3 min at stable 90% neuromuscular blockade with constant-rate infusion of the neuromuscular blocking drug. This produced a relatively small and transient antagonism of blockade--probably of negligible clinical significance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888477     DOI: 10.1093/bja/59.8.995

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

Review 1.  Inflammatory bowel disease: perioperative pharmacological considerations.

Authors:  Ajay Kumar; Moises Auron; Ashish Aneja; Franziska Mohr; Alok Jain; Bo Shen
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

2.  Does cyclosporine affect the duration of action of vecuronium in renal transplant recipients?

Authors:  Koichi Takita; Yukiko Goda; Osamu Kemmotsu; Atsushi Okuyama; Tadayoshi Ito; Hiroshi Sakamoto; Hideyuki Mashio; Hiroshi Kawahigashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

Review 3.  An Update on Systemic Sclerosis and its Perioperative Management.

Authors:  Zyad J Carr; John Klick; Brittany J McDowell; Jean G Charchaflieh; Kunal Karamchandani
Journal:  Curr Anesthesiol Rep       Date:  2020-08-29

4.  Characterization of embryonic cardiac pacemaker and atrioventricular conduction physiology in Xenopus laevis using noninvasive imaging.

Authors:  Heather L Bartlett; Thomas D Scholz; Fred S Lamb; Daniel L Weeks
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-06       Impact factor: 4.733

Review 5.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

Review 6.  Adverse reactions and interactions of the neuromuscular blocking drugs.

Authors:  D Ostergaard; J Engbaek; J Viby-Mogensen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

7.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

Authors:  C Beauvoir; P Peray; J P Daures; J L Peschaud; F D'Athis
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 8.  Monitoring of neuromuscular function in the clinical setting.

Authors:  D Kelly; S J Brull
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct

9.  Anesthetic management of patient with systemic lupus erythematosus and antiphospholipid antibodies syndrome for laparoscopic nephrectomy and cholecystectomy.

Authors:  Rashid Saeed Khokhar; Jumana Baaj; Abdulhamid Al-Saeed; Motasim Sheraz
Journal:  Saudi J Anaesth       Date:  2015-01

Review 10.  [Anaesthesia for noncardiac surgery in a heart-transplanted patient: a clinical case and review of the literature].

Authors:  Oumarou Mahamane Mamane Nassirou; Abdelhamid Jaafari; Abdellatif Chlouchi; Mustapha Bensghir; Charki Haimeur
Journal:  Pan Afr Med J       Date:  2016-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.